BioCentury | Jun 20, 2016
Clinical News

BTA585: Phase IIa suspended enrollment

Aviragen voluntarily suspended enrollment in a double-blind, placebo-controlled, U.K. Phase IIa trial of oral BTA585 after 1 subject had “an increase of a cardiac enzyme level coupled with transient ECG changes,” which led to their...
BioCentury | Apr 18, 2016
Clinical News

BTA585: Phase IIa started

Aviragen (formerly Biota Pharmaceuticals Inc. ) began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 100 mg oral BTA585 twice daily for 7 days in about 60 healthy adult volunteers challenged intranasally with RSV. Subjects...
BioCentury | Mar 7, 2016
Clinical News

BTA585: Phase I data

Top-line data from a placebo-controlled, U.S. Phase I trial in 36 healthy volunteers showed that twice-daily 100, 400 and 600 mg doses of oral BTA585 were generally well tolerated with no serious adverse events reported....
BioCentury | Jan 25, 2016
Clinical News

BTA585: Phase I started

Last month, Biota began a placebo-controlled Phase I trial to evaluate 100, 400 and 600 mg oral BTA585 twice daily in 36 healthy volunteers. Biota Pharmaceuticals Inc. (NASDAQ:BOTA), Alpharetta, Ga. Product: BTA585 Business: Infectious Molecular...
BioCentury | Jan 4, 2016
Clinical News

BTA585: Phase I data

Top-line data from a blinded, placebo-controlled, U.S. Phase I trial in 50 healthy volunteers showed that single doses of 50, 100, 200, 400 and 500 mg oral BTA585 were generally well tolerated with no serious...
BioCentury | Sep 21, 2015
Clinical News

BTA585: Phase I started

Biota began a placebo-controlled, dose-escalation Phase I trial to evaluate 5 single doses of 50-500 mg oral BTA585 in about 50 healthy volunteers. Next quarter, the company plans to start a Phase I trial to...
Items per page:
1 - 6 of 6